Although the precise mechanisms for IGF-1’s beneficial effect in this preclinical model of CIDP are not completely elucidated, our data implicate that IGF-1’s therapeutic properties are partly through its anti-inflammatory activity. This evidence concerns the gene IGF1 and chronic inflammatory demyelinating polyradiculoneuropathy.